In 2014 They Battled For Control. Now Pfizer ' s Read And AstraZeneca ' s Soriot In Different Places

Unfortunately, AstraZeneca ’s revenue predictions have not lived up to Soriot’s promise.

Source: Forbes.com Healthcare News - October 23, 2018 Category: Pharmaceuticals Authors: John LaMattina, Contributor Tags: NYSE:PFE NYSE:AZN NYSE:NVS OTCMKTS:RHHBY Source Type: news